Status:
TERMINATED
Cardiac Allograft Remodeling and Effects of Sirolimus
Lead Sponsor:
University of Nebraska
Conditions:
Cardiac Hypertrophy
Immunosuppression
Eligibility:
All Genders
19-70 years
Phase:
PHASE1
Brief Summary
Cardiac allograft remodeling causes poor quality of life, allograft failure and increased mortality after heart transplantation. Risk factors for cardiac allograft remodeling and its progression are p...
Detailed Description
Heart transplantation has become a well-established treatment option for patients with end-stage heart disease and currently has a one-year survival rate of 90%, a five-year survival rate of 70%, and ...
Eligibility Criteria
Inclusion
- All adult cardiac transplant recipients undergoing heart transplantation at UNMC/TNMC.
Exclusion
- Adult cardiac transplant recipients with acute rejection (ISHLT R\> grade 2) or acute infection.
Key Trial Info
Start Date :
April 24 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2018
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01889992
Start Date
April 24 2013
End Date
September 27 2018
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198